title: [Cetuximab cutaneous adverse drug reactions: a marker of efficacy for metastatic colorectal cancer and head-neck cancer?].
abstract: OBJECTIVE
  Our work aimed to assess, in real conditions, the association between cetuximab's cutaneous adverse drug reactions and the overall survival at 6 months for metastatic colorectal cancer (mCRC) and head-neck cancer.
  
  
  METHODS
  We conducted a retrospective observational study. The 6-month survival was defined as the patient's status evaluated six months after the first administration of cetuximab. Multivariate survival analysis was performed by the Cox model. RESULTS. Between January 2004 to June 2010, 167 patients have been included (97 patients with a mCRC and 70 patients with a head-neck cancer). The occurrence of at least one cutaneous adverse effect is associated with a significantly reduced risk of mortality at 6 months (total population, RR=0.34 [0.20-0.58], p<0.001; mCRC population, RR=0.45 [0.21-0.99], p=0.047; head-neck cancer population, RR=0.25 [0.13-0.50], p<0.001). CONCLUSION. These results show, for the first time in real conditions, the possible link between cutaneous adverse drugs reactions and 6-month survival.
authors.affiliation: Service de pharmacologie médicale et clinique, Centre Midi-Pyrénées de pharmacovigilance, de pharmacoépidémiologie et d'informations sur le médicament, Centre hospitalier universitaire de Toulouse, Toulouse, France.
authors.forename: Marlène
authors.initials: M
authors.lastname: Soussan-Dahan
authors.affiliation: Service de pharmacologie médicale et clinique, Centre Midi-Pyrénées de pharmacovigilance, de pharmacoépidémiologie et d'informations sur le médicament, Centre hospitalier universitaire de Toulouse, Toulouse, France - Laboratoire de pharmacologie médicale et clinique, Faculté de médecine de l'université de Toulouse III Paul Sabatier, Toulouse, France.
authors.forename: Maryse
authors.initials: M
authors.lastname: Lapeyre-Mestre
authors.affiliation: Service de pharmacologie médicale et clinique, Centre Midi-Pyrénées de pharmacovigilance, de pharmacoépidémiologie et d'informations sur le médicament, Centre hospitalier universitaire de Toulouse, Toulouse, France - Laboratoire de pharmacologie médicale et clinique, Faculté de médecine de l'université de Toulouse III Paul Sabatier, Toulouse, France.
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Bondon-Guitton
authors.affiliation: Service d'oncologie médicale, Institut Claudius Regaud, Toulouse, France.
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Delord
authors.affiliation: Service de pharmacologie médicale et clinique, Centre Midi-Pyrénées de pharmacovigilance, de pharmacoépidémiologie et d'informations sur le médicament, Centre hospitalier universitaire de Toulouse, Toulouse, France - Laboratoire de pharmacologie médicale et clinique, Faculté de médecine de l'université de Toulouse III Paul Sabatier, Toulouse, France.
authors.forename: Fabien
authors.initials: F
authors.lastname: Despas
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D054316:Biomarkers, Pharmacological; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D003875:Drug Eruptions / Q000175:diagnosis*; D005260:Female; D006258:Head and Neck Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011379:Prognosis; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D054316:Biomarkers, Pharmacological; D000068818:Cetuximab